<SEC-DOCUMENT>0001104659-25-059524.txt : 20250613
<SEC-HEADER>0001104659-25-059524.hdr.sgml : 20250613
<ACCEPTANCE-DATETIME>20250613194314
ACCESSION NUMBER:		0001104659-25-059524
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250613
DATE AS OF CHANGE:		20250613

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lantern Pharma Inc.
		CENTRAL INDEX KEY:			0001763950
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				463973463
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91536
		FILM NUMBER:		251048142

	BUSINESS ADDRESS:	
		STREET 1:		1920 MCKINNEY AVENUE
		STREET 2:		7TH FLOOR
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75201
		BUSINESS PHONE:		972-277-1136

	MAIL ADDRESS:	
		STREET 1:		1920 MCKINNEY AVENUE
		STREET 2:		7TH FLOOR
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lantern Pharma
		DATE OF NAME CHANGE:	20190108

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bios Equity Partners, LP
		CENTRAL INDEX KEY:			0001813314
		ORGANIZATION NAME:           	
		EIN:				822422973
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		1751 RIVER RUN, SUITE 400
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76107
		BUSINESS PHONE:		817-381-5370

	MAIL ADDRESS:	
		STREET 1:		1751 RIVER RUN, SUITE 400
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76107
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <previousAccessionNumber>0001193125-20-176446</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Bios Equity Partners, LP -->
          <cik>0001813314</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>4</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <dateOfEvent>06/12/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001763950</issuerCIK>
        <issuerCUSIP>51654W101</issuerCUSIP>
        <issuerName>Lantern Pharma Inc.</issuerName>
        <address>
          <com:street1>1920 MCKINNEY AVENUE</com:street1>
          <com:street2>7TH FLOOR</com:street2>
          <com:city>DALLAS</com:city>
          <com:stateOrCountry>TX</com:stateOrCountry>
          <com:zipCode>75201</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Bios Equity Partners, LP</personName>
          <personPhoneNum>(817) 984-9197</personPhoneNum>
          <personAddress>
            <com:street1>1751 River Run, Suite 400</com:street1>
            <com:city>Fort Worth</com:city>
            <com:stateOrCountry>TX</com:stateOrCountry>
            <com:zipCode>76107</com:zipCode>
          </personAddress>
        </notificationInfo>
        <notificationInfo>
          <personName>Rick Jordan; Polsinelli PC</personName>
          <personPhoneNum>(214) 397-0030</personPhoneNum>
          <personAddress>
            <com:street1>4020 Maple Avenue, Suite 300</com:street1>
            <com:city>Dallas</com:city>
            <com:stateOrCountry>TX</com:stateOrCountry>
            <com:zipCode>75219</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001697316</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>BIOS FUND I, LP</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>323335.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>323335.00</sharedDispositivePower>
        <aggregateAmountOwned>323335.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>3.00</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Shared voting and dispositive power consists of shares of common stock, par value $0.0001 per share ("Shares") directly held by Bios Fund I, LP ("Bios Fund I").

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001700297</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>BIOS FUND I QP, LP</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>189117.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>189117.00</sharedDispositivePower>
        <aggregateAmountOwned>189117.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>1.75</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Shared voting and dispositive power consists of Shares directly held by Bios Fund I QP, LP ("Bios Fund I QP").

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001714576</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>BIOS FUND II, LP</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>114272.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>114272.00</sharedDispositivePower>
        <aggregateAmountOwned>114272.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>1.06</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Shared voting and dispositive power consists of Shares directly held by Bios Fund II, LP ("Bios Fund II").

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001716869</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>BIOS FUND II QP, LP</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>373178.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>373178.00</sharedDispositivePower>
        <aggregateAmountOwned>373178.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>3.46</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Shared voting and dispositive power consists of Shares directly held by Bios Fund II QP, LP ("Bios Fund II QP").

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001728851</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>BIOS FUND II NT, LP</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>49957.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>49957.00</sharedDispositivePower>
        <aggregateAmountOwned>49957.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>0.46</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Shared voting and dispositive power consists of Shares directly held by Bios Fund II NT, LP ("Bios Fund II NT").

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001813311</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>BP DIRECTORS, LP</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>26093.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>26093.00</sharedDispositivePower>
        <aggregateAmountOwned>26093.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>0.24</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Shared voting and dispositive power consists of Shares directly held by BP Directors, LP ("BP Directors").

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001813314</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>BIOS EQUITY PARTNERS, LP</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>TX</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>538545.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>538545.00</sharedDispositivePower>
        <aggregateAmountOwned>538545.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.99</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Shared voting and dispositive power consists (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP and (iii) 26,093 Shares directly held by BP Directors. Bios Equity Partners, LP ("Bios Equity I") is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. In its capacity as the general partner of these entities, Bios Equity I may be deemed to have shared voting and/or dispositive power with respect to securities directly held by these entities.

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001813313</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>BIOS EQUITY PARTNERS II, LP</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>TX</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>537407.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>537407.00</sharedDispositivePower>
        <aggregateAmountOwned>537407.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.98</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Shared voting and dispositive power consists of (i) 114,272 Shares directly held by Bios Fund II, (ii) 373,178 Shares directly held by Bios Fund II QP and (iii) 49,957 Shares directly held by Bios Fund II NT. Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. In its capacity as the general partner of these entities, Bios Equity II may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities.

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001813270</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>CAVU MANAGEMENT, LP</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>TX</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1075952.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1075952.00</sharedDispositivePower>
        <aggregateAmountOwned>1075952.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>9.98</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management") is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Cavu Management may be deemed to have shared voting and/or dispositive power with respect to securities directly held by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities").

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001813845</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>BIOS CAPITAL MANAGEMENT, LP</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>TX</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1075952.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1075952.00</sharedDispositivePower>
        <aggregateAmountOwned>1075952.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>9.98</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Capital Management, LP ("Bios Management") is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Bios Management may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001813310</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>CAVU ADVISORS, LLC</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>TX</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1075952.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1075952.00</sharedDispositivePower>
        <aggregateAmountOwned>1075952.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>9.98</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, LLC ("Cavu Advisors") is the general partner of Cavu Management, and therefore may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001813844</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>BIOS ADVISORS GP, LLC</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>TX</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1075952.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1075952.00</sharedDispositivePower>
        <aggregateAmountOwned>1075952.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>9.98</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001813316</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>LESLIE W. KREIS</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1075952.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1075952.00</sharedDispositivePower>
        <aggregateAmountOwned>1075952.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>9.98</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001789490</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>AARON G.L. FLETCHER</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1075952.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1075952.00</sharedDispositivePower>
        <aggregateAmountOwned>1075952.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>9.98</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, par value $0.0001 per share</securityTitle>
        <issuerName>Lantern Pharma Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>1920 MCKINNEY AVENUE</com:street1>
          <com:street2>7TH FLOOR</com:street2>
          <com:city>DALLAS</com:city>
          <com:stateOrCountry>TX</com:stateOrCountry>
          <com:zipCode>75201</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>This Amendment No. 4 hereby amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "Commission") on June 15, 2020 (the "Original Schedule 13D"), as amended by the statement on Schedule 13D/A filed with the Commission on March 22, 2022 ("Amendment No. 1"), as further amended by the statement on Schedule 13D/A filed with the Commission on December 1, 2023 ("Amendment No. 2"), as further amended by the statement on Schedule 13D/A filed with the Commission on March 1, 2024 ("Amendment No. 3" and, together with the Original Schedule 13D, Amendment No. 1 and Amendment No. 2, the "Prior Statements"). The securities to which the Schedule 13D relates are the shares of common stock, par value $0.0001 per share (the "Shares"), of Lantern Pharma, Inc., a Delaware corporation (the "Issuer").</commentText>
      </item1>
      <item5>
        <percentageOfClassSecurities>The information contained on the cover pages of this Schedule 13D is incorporated herein by reference.</percentageOfClassSecurities>
        <numberOfShares>The information contained on the cover pages of this Schedule 13D is incorporated herein by reference.</numberOfShares>
        <transactionDesc>On May 27, 2025, (i) Bios Fund I sold 6,479 Shares, Bios Fund I QP sold 3,790 Shares, (iii) Bios Fund II sold 2,290 Shares, (iv) Bios Fund II QP sold 7,478 Shares and (v) Bios Fund II NT sold 1,000 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $3.05 on the open market at prices ranging between $2.87 to $3.21, inclusive.

On May 28, 2025, (i) Bios Fund I sold 4,620 Shares, Bios Fund I QP sold 2,702 Shares, (iii) Bios Fund II sold 1,632 Shares, (iv) Bios Fund II QP sold 5,332 Shares and (v) Bios Fund II NT sold 714 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $2.87 on the open market at prices ranging between $2.85 to $2.94, inclusive.

On May 29, 2025, (i) Bios Fund I sold 6,221 Shares, Bios Fund I QP sold 3,639 Shares, (iii) Bios Fund II sold 2,199 Shares, (iv) Bios Fund II QP sold 7,180 Shares and (v) Bios Fund II NT sold 961 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $3.03 on the open market at prices ranging between $3.00 to $3.13, inclusive.

On June 10, 2025, (i) Bios Fund I sold 5 Shares, Bios Fund I QP sold 3 Shares, (iii) Bios Fund II sold 2 Shares, (iv) Bios Fund II QP sold 5 Shares and (v) Bios Fund II NT sold 1 Share, all such sales in clauses (i)-(v) of this sentence being sold at a price of $3.40 on the open market.

On June 11, 2025, (i) Bios Fund I sold 293 Shares, Bios Fund I QP sold 171 Shares, (iii) Bios Fund II sold 103 Shares, (iv) Bios Fund II QP sold 338 Shares and (v) Bios Fund II NT sold 45 Shares, all such sales in clauses (i)-(v) of this sentence being sold at a price of $3.40 on the open market.

On June 12, 2025, (i) Bios Fund I sold 18,678 Shares, Bios Fund I QP sold 10,925 Shares, (iii) Bios Fund II sold 6,601 Shares, (iv) Bios Fund II QP sold 21,557 Shares and (v) Bios Fund II NT sold 2,886 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $3.38 on the open market at prices ranging between $3.25 to $3.57, inclusive.

On June 13, 2025, (i) Bios Fund I sold 12,319 Shares, Bios Fund I QP sold 7,206 Shares, (iii) Bios Fund II sold 4,354 Shares, (iv) Bios Fund II QP sold 14,218 Shares and (v) Bios Fund II NT sold 1,903 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $3.09 on the open market at prices ranging between $3.05 to $3.26, inclusive.

The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above.</transactionDesc>
        <listOfShareholders>Except as described in this Amendment No. 4, to the knowledge of the Reporting Persons, only the Reporting Persons have the right to receive or the power to direct receipt of dividends from, or proceeds from the sale of, the Shares reported by the Schedule 13D.</listOfShareholders>
        <date5PercentOwnership>Not applicable.</date5PercentOwnership>
      </item5>
      <item7>
        <filedExhibits>Exhibit 99.1: Joint Filing Agreement, dated June 23, 2020 (incorporated by reference to the Original Schedule 13D, filed on June 23, 2020).</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>BIOS FUND I, LP</signatureReportingPerson>
        <signatureDetails>
          <signature>John Fucci</signature>
          <title>Attorney-in-Fact</title>
          <date>06/13/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>BIOS FUND I QP, LP</signatureReportingPerson>
        <signatureDetails>
          <signature>John Fucci</signature>
          <title>Attorney-in-Fact</title>
          <date>06/13/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>BIOS FUND II, LP</signatureReportingPerson>
        <signatureDetails>
          <signature>John Fucci</signature>
          <title>Attorney-in-Fact</title>
          <date>06/13/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>BIOS FUND II QP, LP</signatureReportingPerson>
        <signatureDetails>
          <signature>John Fucci</signature>
          <title>Attorney-in-Fact</title>
          <date>06/13/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>BIOS FUND II NT, LP</signatureReportingPerson>
        <signatureDetails>
          <signature>John Fucci</signature>
          <title>Attorney-in-Fact</title>
          <date>06/13/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>BP DIRECTORS, LP</signatureReportingPerson>
        <signatureDetails>
          <signature>John Fucci</signature>
          <title>Attorney-in-Fact</title>
          <date>06/13/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>BIOS EQUITY PARTNERS, LP</signatureReportingPerson>
        <signatureDetails>
          <signature>John Fucci</signature>
          <title>Attorney-in-Fact</title>
          <date>06/13/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>BIOS EQUITY PARTNERS II, LP</signatureReportingPerson>
        <signatureDetails>
          <signature>John Fucci</signature>
          <title>Attorney-in-Fact</title>
          <date>06/13/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>CAVU MANAGEMENT, LP</signatureReportingPerson>
        <signatureDetails>
          <signature>John Fucci</signature>
          <title>Attorney-in-Fact</title>
          <date>06/13/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>BIOS CAPITAL MANAGEMENT, LP</signatureReportingPerson>
        <signatureDetails>
          <signature>John Fucci</signature>
          <title>Attorney-in-Fact</title>
          <date>06/13/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>CAVU ADVISORS, LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>John Fucci</signature>
          <title>Attorney-in-Fact</title>
          <date>06/13/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>BIOS ADVISORS GP, LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>John Fucci</signature>
          <title>Attorney-in-Fact</title>
          <date>06/13/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>LESLIE W. KREIS</signatureReportingPerson>
        <signatureDetails>
          <signature>John Fucci</signature>
          <title>Attorney-in-Fact</title>
          <date>06/13/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>AARON G.L. FLETCHER</signatureReportingPerson>
        <signatureDetails>
          <signature>John Fucci</signature>
          <title>Attorney-in-Fact</title>
          <date>06/13/2025</date>
        </signatureDetails>
      </signaturePerson>
      <commentText>John Fucci is signing on behalf of the Reporting Persons pursuant to a power of attorney dated May 22, 2025, 2024, which was previously filed with the Commission as an exhibit to Forms 4 filed by the Reporting Persons on May 29, 2025 (SEC File No. 001-39318)</commentText>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
